Products
Data
Feature
Plans
Request Demo
Sign Up for Free
Blog
Valuable Targets
Advanced Tech.
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Alexion Pharmaceuticals, Inc Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
7 August 2026
Alexion Pharmaceuticals, Inc BD opportunity scan covering pipeline ownership, stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale using PatSnap MCP.
Read →
Latest Hotspot
8 min read
Celgene Corporation Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
7 August 2026
Celgene Corporation BD opportunity scan covering pipeline ownership, stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale using PatSnap MCP.
Read →
Latest Hotspot
8 min read
Cephalon, Inc Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
7 August 2026
Cephalon, Inc BD opportunity scan covering pipeline ownership, stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale using PatSnap MCP.
Read →
Latest Hotspot
8 min read
Danaher Corporation Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
7 August 2026
Danaher Corporation BD opportunity scan covering pipeline ownership, stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale using PatSnap MCP.
Read →
Latest Hotspot
8 min read
NCT07707674 XNW-28012 Metastatic Pancreatic Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07707674 clinical trial report covering XNW-28012, Phase 1, endpoints, sponsor, geography, readout timing and development white space.
Read →
Latest Hotspot
8 min read
NCT07714798 Universal STAR-T Cell(BriSTAR Immunotech) Myasthenia Gravis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07714798 clinical trial report covering Universal STAR-T Cell(BriSTAR Immunotech), Phase 1, endpoints, sponsor, geography, readout timing and developmen
Read →
Latest Hotspot
8 min read
NCT07717086 HYR-PB21 Pain, Postoperative Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07717086 clinical trial report covering HYR-PB21, Phase 1, endpoints, sponsor, geography, readout timing and development white space.
Read →
Latest Hotspot
8 min read
NCT07719088 Psilocybin disorder of aging Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07719088 clinical trial report covering Psilocybin, Phase 1, endpoints, sponsor, geography, readout timing and development white space.
Read →
Latest Hotspot
8 min read
NCT07615660 Bulumtatug fuvedotin Advanced Malignant Solid Neoplasm Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07615660 clinical trial report covering Bulumtatug fuvedotin, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Read →
Latest Hotspot
8 min read
NCT07612891 INV-6452 Locally Advanced Malignant Solid Neoplasm Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07612891 clinical trial report covering INV-6452, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Read →
Latest Hotspot
8 min read
NCT07615283 Zeprumetostat Peripheral T-Cell Lymphoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07615283 clinical trial report covering Zeprumetostat, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Read →
Latest Hotspot
8 min read
NCT07612787 ALK.CAR-T cells(University of Turin/Boston Children) Relapse multiple myeloma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07612787 clinical trial report covering ALK.CAR-T cells(University of Turin/Boston Children), Phase 1/2, endpoints, sponsor, geography, readout timing a
Read →
<
1
<<
822
823
824
825
826
>>
2260
>